MicroRNA-134 actives lipoprotein lipase-mediated lipid accumulation and inflammatory response by targeting angiopoietin-like 4 in THP-1 macrophages

Lan, Gang; Xie, Wei; Li, Liang; Zhang, Min; Liu, Dan; Tan, Yanhong; Cheng, Haipeng; Gong, Duo; Huang, Chong; Zheng, Xi-Long; Yin, Wang; Tang, Chao-Ke

doi:10.1016/j.bbrc.2015.10.158

Cited by 41 publications

(33 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11, 12 Our group has recently shown that miR-590, miR-134, and miR-467b can regulate LPL expression in either in vitro or in vivo experiments. [13][14][15][16][17] As a polyphenic miRNA, miR-182 is known to be involved …”

Section: Mir-182 Promotes Atherogenesismentioning

confidence: 99%

MicroRNA-182 Promotes Lipoprotein Lipase Expression and Atherogenesisby Targeting Histone Deacetylase 9 in Apolipoprotein E-Knockout Mice

Cheng

Gong

Zhao

et al. 2017

Circ J

Self Cite

View full text Add to dashboard Cite

Section: Mir-182 Promotes Atherogenesismentioning

confidence: 99%

MicroRNA-182 Promotes Lipoprotein Lipase Expression and Atherogenesisby Targeting Histone Deacetylase 9 in Apolipoprotein E-Knockout Mice

Cheng

Gong

Zhao

et al. 2017

Circ J

Self Cite

View full text Add to dashboard Cite

“…miR-23a-5p and miR-212 increase foam cell formation by reducing cholesterol efflux from macrophages through ABCA1 [31,78]. miR-34 increases the binding capacity of oxLDL to macrophages by facilitating bridging between lipoprotein lipase (LPL) and LOX-1 [79]. Conversely, miR-27 and miR-590 inhibit LPL expression to prevent macrophage lipid accumulation and cytokine release [77,80,81].…”

Section: Monocyte Recruitment Macrophage Differentiation and Foam Cementioning

confidence: 99%

MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis

Solly

Dimasi

Bursill

et al. 2019

JCM

View full text Add to dashboard Cite

Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Atherosclerosis develops over several decades and is mediated by a complex interplay of cellular mechanisms that drive a chronic inflammatory milieu and cell-to-cell interactions between endothelial cells, smooth muscle cells and macrophages that promote plaque development and progression. While there has been significant therapeutic advancement, there remains a gap where novel therapeutic approaches can complement current therapies to provide a holistic approach for treating atherosclerosis to orchestrate the regulation of complex signalling networks across multiple cell types and different stages of disease progression. MicroRNAs (miRNAs) are emerging as important post-transcriptional regulators of a suite of molecular signalling pathways and pathophysiological cellular effects. Furthermore, circulating miRNAs have emerged as a new class of disease biomarkers to better inform clinical diagnosis and provide new avenues for personalised therapies. This review focusses on recent insights into the potential role of miRNAs both as therapeutic targets in the regulation of the most influential processes that govern atherosclerosis and as clinical biomarkers that may be reflective of disease severity, highlighting the potential theranostic (therapeutic and diagnostic) properties of miRNAs in the management of cardiovascular disease.

show abstract

“…However, a recent study showed that miR‐182 has a significant role in inhibiting oxidative stress and apoptosis via targeting TLR‐4 in vitro (Figure C). MiR320a, miR‐378, miR‐758 and miR‐134 are other biomarkers involved in lipid metabolism and the development of atherosclerosis . Although elevated miR‐320a and low levels of miR‐320b contribute to atherogenesis, Schrottmaier et al have shown that elevated miR‐320a could control the electrophilic stress response induced by oxidized phospholipids in endothelial cells .…”

Section: Preclinical Studies Of Mirnas In Atherosclerosismentioning

confidence: 99%

“…MiR‐758 directly can reduce cellular cholesterol efflux and increase pathologies associated with dyslipidemia by targeting the ABCA1 and CD36 genes . Although miR‐134 promotes lipid accumulation and pro‐inflammatory cytokine secretion, it can also suppress angiotensin II‐induced VSMC dysfunction and reduce neointimal formation by targeting angiotensin II type 1 receptor (AT1R) . Furthermore, miR‐20 also decreased cholesterol efflux and increased cholesterol content by downregulation ABCA1 expression in vitro/vivo (Figure A).…”

Section: Preclinical Studies Of Mirnas In Atherosclerosismentioning

confidence: 99%

Diagnostic and theranostic microRNAs in the pathogenesis of atherosclerosis

Shoeibi

2019

Acta Physiologica

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a group of small single strand and noncoding RNAs that regulate several physiological and molecular signalling pathways. Alterations of miRNA expression profiles may be involved with pathophysiological processes underlying the development of atherosclerosis and cardiovascular diseases, including changes in the functions of the endothelial cells and vascular smooth muscle cells, such as cell proliferation, migration and inflammation, which are involved in angiogenesis, macrophage function and foam cell formation. Thus, miRNAs can be considered to have a crucial role in the progression, modulation and regulation of every stage of atherosclerosis. Such potential biomarkers will enable us to predict therapeutic response and prognosis of cardiovascular diseases and adopt effective preclinical and clinical treatment strategies. In the present review article, the current data regarding the role of miRNAs in atherosclerosis were summarized and the potential miRNAs as prognostic, diagnostic and theranostic biomarkers in preclinical and clinical studies were further discussed. The highlights of this review are expected to present opportunities for future research of clinical therapeutic approaches in vascular diseases resulting from atherosclerosis with an emphasis on miRNAs. K E Y W O R D Satherosclerosis, diagnosis, miRNA, prognosis, therapeutic approaches 2 of 24 | SHOEIBI Because miRNAs have a relatively high stability under the physiological conditions of mammals, they can be used as prognostic and diagnostic markers for diseases, such as atherosclerosis. This review aims to describe and summarize miRNA expression studies in model animal experiments and clinical practices related to atherosclerosis. The expressed pattern of miRNAs contributing to atherosclerosis at different stages of the atherosclerotic process in comparison with healthy arteries is also discussed.

show abstract

MicroRNA-134 actives lipoprotein lipase-mediated lipid accumulation and inflammatory response by targeting angiopoietin-like 4 in THP-1 macrophages

Cited by 41 publications

References 29 publications

MicroRNA-182 Promotes Lipoprotein Lipase Expression and Atherogenesisby Targeting Histone Deacetylase 9 in Apolipoprotein E-Knockout Mice

MicroRNA-182 Promotes Lipoprotein Lipase Expression and Atherogenesisby Targeting Histone Deacetylase 9 in Apolipoprotein E-Knockout Mice

MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis

Diagnostic and theranostic microRNAs in the pathogenesis of atherosclerosis

Contact Info

Product

Resources

About